ライフサイエンスコーパス: cAMP phosphodiesterase

1 nd characterized the enzyme CpdA, a putative cAMP phosphodiesterase.

2 resence and absence of IBMX, an inhibitor of cAMP phosphodiesterase.

3 mice of partial inhibition of a hippocampal cAMP phosphodiesterase.

4 mmatory disorders express elevated levels of cAMP phosphodiesterase.

5 the active site of PDE3A as well as in other cAMP phosphodiesterases.

6 actamase domain, a superfamily that includes cAMP phosphodiesterases.

7 ase-4 (PDE4) inhibitor rolipram, but not the cAMP phosphodiesterase-3 (PDE3) inhibitor cilostamide, c

8 cGMP-inhibited cAMP phosphodiesterase 3A (PDE3A) is expressed in mouse

9 Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promis

10 re, we show that the genetic ablation of one cAMP-phosphodiesterase 4 subtype, PDE4B, is sufficient t

11 Restoring cAMP levels using the oral cAMP phosphodiesterase-4 inhibitor, apremilast, improves

12 Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP an

13 kolin together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but

14 ded by protein kinase A-RII, beta-arrestin2, cAMP phosphodiesterase-4D3, and cAMP phosphodiesterase-4

15 a-arrestin2, cAMP phosphodiesterase-4D3, and cAMP phosphodiesterase-4D5.

16 We demonstrate that CpdA possesses 3',5'-cAMP phosphodiesterase activity in vitro and that it uti

17 o alanine or asparagine suppressed the 2',3'-cAMP phosphodiesterase activity of Rv0805 without advers

18 Rp-Br-cAMP[S]) and when the cGMP-inhibitable cAMP phosphodiesterase activity was inhibited by pretrea

19 Drosophila, at least in part, by inhibiting cAMP phosphodiesterase activity.

20 m of of the calmodulin-dependent activity of cAMP phosphodiesterase and for binding affinity to rat u

21 The dunce cAMP-phosphodiesterase and rutabaga adenylyl cyclase gen

22 ing neurons in response to NMDA receptor and cAMP phosphodiesterase antagonists and occurred graduall

23 re mediated by cAMP, as injection of cAMP or cAMP phosphodiesterase disrupts wave propagation and res

24 minal receiver domain linked to a C-terminal cAMP-phosphodiesterase domain.

25 In an OK cell clone that overexpressed cAMP phosphodiesterase, dopamine did not inhibit phospha

26 signaling by silencing the expression of the cAMP phosphodiesterase DUNCE.

27 reas reducing cAMP pulse size with exogenous cAMP phosphodiesterase during stream formation causes ce

28 terases, and in particular the high-affinity cAMP phosphodiesterase encoded by PDE2, have real potent

29 Although the two cAMP phosphodiesterase genes PDE1 and PDE2 had overlappi

30 IBMX, an inhibitor of cAMP phosphodiesterase, had no significant effect on ATP

31 t can predict enhanced clinical responses to cAMP phosphodiesterase inhibition.

32 ositively coupled to adenylyl cyclase, and a cAMP phosphodiesterase inhibitor ameliorated the physiol

33 s were transient, but in the presence of the cAMP phosphodiesterase inhibitor isobutylmethylxanthine

34 ing that CGRP gene transfer alone and with a cAMP phosphodiesterase inhibitor may be useful for the t

35 hanged and decreases in PAP in response to a cAMP phosphodiesterase inhibitor were enhanced by AdRSVC

36 entiation inducers methylisobutylxanthine (a cAMP phosphodiesterase inhibitor) or Forskolin, both of

37 pocytes induced by methylisobutylxanthine (a cAMP phosphodiesterase inhibitor), dexamethasone, and in

38 ling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induce

39 chronic (12-15 day) exposure to the type IV cAMP phosphodiesterase inhibitor, Ro20-1724, were examin

40 mutant phenotypes, an effect mimicked by the cAMP phosphodiesterase inhibitor, rolipram.

41 In contrast, the cAMP phosphodiesterase inhibitor, theophylline, inhibite

42 rtant regulator of external cAMP levels, the cAMP phosphodiesterase inhibitor, we can explain the nat

43 e presence of 3-isobutyl-1-methylxanthine, a cAMP phosphodiesterase inhibitor.

44 d by pretreatment with rolipram, a selective cAMP phosphodiesterase inhibitor.

45 3 d of treatment with milrinone, a type III cAMP phosphodiesterase inhibitor.

46 Theophylline, a competitive inhibitor of cAMP phosphodiesterase, inhibits the maturation of oocyt

47 One domain is a cAMP phosphodiesterase (Km approximately 5 microM); the

48 eletion of the gene encoding a high-affinity cAMP phosphodiesterase (NCU00478).

49 s strongly reduces the function of the Dunce cAMP phosphodiesterase PDE-4 by disrupting a conserved a

50 Since milrinone, an inhibitor of cAMP phosphodiesterase (PDE) 3, did not reverse the effe

51 responsible for this change in cAMP levels, cAMP phosphodiesterase (PDE) and adenylyl cyclase activi

52 ions affecting the Schizosaccharomyces pombe cAMP phosphodiesterase (PDE) gene cgs2+ were identified

53 we have tested the hypothesis that specific cAMP phosphodiesterase (PDE) isoforms of the PDE4D famil

54 We investigated the role of cAMP phosphodiesterase (PDE) isozymes in these regulator

55 ease in cAMP, brought about by the action of cAMP phosphodiesterase (PDE), is thought to initiate ger

56 ne whether a cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE), PDE4, is expressed in hum

57 mulates filamentation in strains lacking the cAMP phosphodiesterase PDE2, even in the absence of nitr

58 ared the roles of the high- and low-affinity cAMP phosphodiesterases, Pde2p and Pde1p in stress, adhe

59 osine 3',5'-cyclic monophosphate inactivates cAMP phosphodiesterase (PDE3A); however, millimolar conc

60 tion induced by concurrent inhibition of the cAMP phosphodiesterases PDE4 and PDE8.

61 By blocking cAMP degradation, type 4 cAMP phosphodiesterase (PDE4) inhibitors activate cAMP-m

62 Type 4 cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE4) inhibitors and other agen

63 The airways of mice deficient in the cAMP phosphodiesterase PDE4D gene are refractory to musc

64 cAMP phosphodiesterases PDEB1 and PDEB2 were found to be

65 To understand the role cAMP phosphodiesterases (PDEs) play in the regulation of

66 sses of adenosine 3'5' cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis in ch

67 sation evolved, we studied the origin of the cAMP phosphodiesterase PdsA and its inhibitor PdiA, whic

68 yl M anion-exchange chromatography, showed a cAMP phosphodiesterase peak that was minimally sensitivi

69 tyl-1-methylxanthine (IBMX), an inhibitor of cAMP phosphodiesterase, potentiated PGE2-induced suppres

70 ERK2 phosphorylates the cAMP phosphodiesterase REG A that reduces the internal c

71 s in which the gene encoding the cytoplasmic cAMP phosphodiesterase RegA is inactivated form small ag

72 eceptor DhkA, it reduces the activity of the cAMP phosphodiesterase RegA such that cAMP levels can in

73 ng the adenylate cyclases ACG or ACR, or the cAMP phosphodiesterase RegA.

74 ressor studies indicate that the cyclic AMP (cAMP) phosphodiesterase RegA and the cAMP-dependent prot

75 a mycobacterial strain deleted for the known cAMP phosphodiesterase (Rv0805c) combined with mass spec

76 further identified mutations in the atypical cAMP phosphodiesterase rv1339 that suppress both fatty a

77 creted protein inhibitor of an extracellular cAMP phosphodiesterase selects for spirals.

78 the effects of phosphodiesterase 4 (PDE4), a cAMP phosphodiesterase that is phosphorylated and inhibi

79 on and DON production, and Pde2 is the major cAMP phosphodiesterase to negatively regulate DON biosyn